Ovarian cancer complicating pregnancy is uncommon by any measure, with an estimated incidence ranging from one in 12,000 to one in 47,000 pregnancies. Within that already narrow category, high-grade serous carcinoma occupies a particularly concerning niche. It is an aggressive epithelial ovarian cancer, and its diagnosis during early gestation is exceptionally rare. The difficulty begins with symptoms. Abdominal bloating, discomfort and nausea are hallmark complaints of normal early pregnancy, yet they are also the vague presenting signs of ovarian malignancy. This overlap means that a growing tumor can be mistaken for pregnancy-related changes, delaying recognition of a potentially life-threatening disease at a stage when both maternal health and the ongoing pregnancy hang in the balance.

In the reported case, the patient arrived with lower abdominal pain and progressive abdominal distension that had persisted for approximately two weeks. She had previously delivered two children and reported no personal or family history of malignancy, factors that might otherwise have lowered suspicion. Clinical examination, however, identified a palpable pelvic mass, prompting further investigation. Ultrasonography confirmed a viable pregnancy but also revealed a large mass measuring 10 by 13 centimeters in the left adnexa, the anatomical region surrounding the ovary. The mass was complex, containing both solid and cystic components separated by internal septations, and it was accompanied by ascites, an abnormal accumulation of fluid within the abdominal cavity, as well as omental nodularity. Each of these features independently raised concern; together, they painted a picture strongly suggestive of ovarian malignancy.

Laboratory testing added another layer of complexity. The patient’s cancer antigen 125, or CA-125, level was elevated at 332 units per milliliter. CA-125 is a widely used tumor marker in ovarian cancer management, but it carries a well-known limitation in pregnancy: it may rise naturally during early gestation and cannot independently establish a diagnosis of ovarian cancer. In this case, the elevated marker could not be interpreted in isolation, but when considered alongside the suspicious imaging findings, it strengthened the argument for further evaluation. This interplay between a marker that is unreliable in pregnancy and imaging features that are difficult to interpret in a gravid abdomen illustrates precisely why early-stage diagnosis of ovarian malignancy during gestation remains such a formidable clinical challenge.

Given the concern for advanced malignancy, the clinical team turned to contrast-enhanced computed tomography, a decision that required careful weighing of potential maternal benefit against fetal risk from ionizing radiation. The patient was counseled about both dimensions, and informed consent was obtained before the scan proceeded. The CT confirmed the complex adnexal mass, the ascites and peritoneal nodularity, findings suggesting that the disease might have spread beyond the ovary. The step from ultrasound to CT in a pregnant patient is not taken lightly, and the case demonstrates how, when suspicion of advanced cancer is high enough, the potential threat to the mother can justify imaging that would otherwise be deferred during gestation.

The case was then reviewed by a multidisciplinary team that brought together gynecologic oncology, radiology and anesthesia specialists. The clinicians weighed the suspected advanced stage of the disease, the potential threat to maternal health, and the implications of any treatment for the ongoing pregnancy. After detailed counselling and discussion of the available options, the patient, who had completed her reproductive plans, chose definitive surgical management. This decision-making process, documented step by step in the report, reflects the reality that no standardized pathway exists for such rare presentations. Each element, from the timing of intervention to the extent of surgery, had to be individualized on the basis of the specific clinical circumstances and the patient’s own values and preferences.

During staging laparotomy, surgeons identified a large solid-cystic tumor arising from the left ovary, along with ascites and multiple nodules involving the omentum and the peritoneal lining. Intraoperative frozen-section analysis, which allows rapid microscopic assessment of tissue during surgery, suggested epithelial ovarian carcinoma. The surgical team subsequently performed a total abdominal hysterectomy, bilateral salpingo-oophorectomy and infracolic omentectomy, removing the uterus, both ovaries and fallopian tubes, and part of the omentum. Final histopathological examination confirmed high-grade serous carcinoma, classified as FIGO stage IIIB. Under the microscope, the tumor displayed the characteristic malignant features of this entity, including marked nuclear abnormalities and frequent atypical cell divisions. Immunohistochemical testing demonstrated strong nuclear positivity for WT1, a marker that supported the diagnosis of serous ovarian carcinoma and helped distinguish it from other epithelial subtypes.

Following an uneventful postoperative recovery, the patient received adjuvant chemotherapy with paclitaxel and carboplatin, a standard regimen for this tumor type. At the reported one-year follow-up, she remained disease-free and continued regular surveillance. The case also raises important considerations about treatment timing during pregnancy. Surgical intervention for suspected ovarian malignancy during gestation is generally postponed until the second trimester when feasible, a window considered safest for the developing fetus. However, when imaging suggests advanced malignancy and maternal health may be at risk, intervention during the first trimester may become necessary. The authors emphasize that such decisions require individualized assessment, informed consent and coordination among the relevant specialists, rather than rigid adherence to any single timeline.

The report also turns to the potential role of hereditary cancer susceptibility. High-grade serous ovarian carcinoma is frequently associated with alterations involving the TP53 gene, while inherited mutations in BRCA1 and BRCA2 can influence both cancer risk and treatment options. Because of the patient’s relatively young age at diagnosis, genetic counselling and BRCA testing were recommended. In this instance, however, testing could not be performed because of logistical constraints, leaving her genetic status unknown. This gap highlights a practical barrier that persists in many health care settings: even when genetic evaluation is clearly indicated, access and resources may determine whether it actually takes place, with potential consequences for the patient’s relatives and for future treatment decisions.

As a single-patient case report, the findings cannot establish how frequently high-grade serous ovarian carcinoma occurs during pregnancy, nor can they determine which treatment approach produces the best outcomes across different clinical circumstances. Nevertheless, the case provides a concrete example of the diagnostic and therapeutic decisions involved when a potentially advanced ovarian malignancy is discovered during early gestation. The authors summarize the central lesson in their own words: early imaging, appropriate surgical planning, and multidisciplinary decision-making are essential for optimal maternal outcomes. Overall, the report underscores the importance of thoroughly evaluating suspicious adnexal masses during pregnancy, particularly when complex imaging features, ascites and elevated tumor markers converge to raise concern for malignancy. In these uncommon and challenging clinical situations, early recognition, coordinated specialist care and individualized treatment planning may make the decisive difference in protecting maternal health while navigating the profound stakes of early pregnancy.

Subject of Research: High-grade serous ovarian carcinoma diagnosed during early pregnancy

Article Title: Rare ovarian cancer diagnosed during early pregnancy highlights diagnostic challenges

Article References: Rare ovarian cancer diagnosed during early pregnancy highlights diagnostic challenges. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ovarian cancer, high-grade serous carcinoma, pregnancy, adnexal mass, CA-125, WT1, staging laparotomy, BRCA1, BRCA2, chemotherapy, multidisciplinary care, Oncoscience

High-grade serous cancer, abbreviated HGSC, is the most common and most lethal form of epithelial ovarian cancer. A growing body of evidence indicates that many of these tumors actually originate in the fimbriated end of the fallopian tube, in a precursor lesion known as serous tubal intraepithelial carcinoma, or STIC. This insight has reshaped the field, prompting researchers to compare molecular changes across the full trajectory of the disease, from healthy fallopian tube epithelium through STIC to frank high-grade serous carcinoma. The Belfast-led team took precisely this approach, examining KCNK1 at three distinct molecular levels: DNA methylation, mRNA expression and immunohistochemical protein staining. By triangulating across these layers of biological information, the researchers sought to determine whether KCNK1 could serve as a reliable molecular signpost marking the transition from normal tissue to malignancy.

KCNK1 belongs to the two-pore domain potassium channel family, a class of leak channels that help set the resting membrane potential of cells. Ion channels have increasingly been recognized as contributors to cancer biology, influencing proliferation, migration, apoptosis and the electrical signaling that tumors hijack to support their growth. What makes the new study particularly compelling is the consistency of the signal across multiple independent cohorts and analytical platforms. The researchers found that KCNK1 mRNA expression was significantly higher in high-grade serous cancer than in normal fallopian tube tissue. This elevation was not a subtle statistical whisper but a robust difference that held up when the team extended their analysis to broader panels of epithelial ovarian carcinomas, including Type I tumors and lower-grade serous disease.

The prognostic implications of these expression patterns proved equally striking. In three independent patient cohorts, higher KCNK1 expression in Type I and lower-grade ovarian cancers predicted significantly improved overall survival. In other words, patients whose tumors expressed more of this potassium channel tended to live longer, a finding that was replicated across geographically distinct collections of samples from Belfast, Nottingham and Vancouver. Within high-grade serous cancer specifically, the team turned to immunohistochemistry, staining tissue microarrays for the KCNK1 protein. Here again, high protein expression independently predicted improved outcome, meaning that even after accounting for established clinical variables, KCNK1 staining status remained a significant predictor of survival. This independence is critical for any biomarker aspiring to clinical use, as it demonstrates added value beyond what clinicians already know.

But the most dramatic result of the study concerns DNA methylation, the chemical tagging of cytosine bases in the KCNK1 gene that can alter its activity without changing the underlying DNA sequence. When the researchers measured KCNK1 methylation levels, they discovered a diagnostic capability that stunned them: 98 percent sensitivity and 98 percent specificity in distinguishing high-grade serous cancer from normal fallopian tube. To appreciate how remarkable those numbers are, one need only look at the current gold standard biomarker, CA-125. This protein, measured in blood for decades, suffers from low sensitivity in early-stage disease and is frequently elevated in benign conditions such as endometriosis, fibroids and even menstruation, which produces false positives that trigger unnecessary anxiety and invasive follow-up procedures. The KCNK1 methylation marker significantly outperformed CA-125 in specificity, correctly ruling out cancer in patients who do not have it.

The technical machinery behind these measurements reflects the sophistication of modern molecular pathology. The team assessed methylation status across matched cohorts of 48 cancer samples versus 48 normal samples, quantified mRNA expression using techniques including digital droplet PCR, an ultra-sensitive method that partitions samples into thousands of tiny droplets to count individual target molecules, and evaluated protein expression on tissue microarrays, which allow hundreds of tumor cores to be stained and scored in a single experiment. Samples were drawn from the Northern Ireland Biobank, an NHS Research Ethics Committee-approved research tissue bank operating under a Human Tissue Authority licence, with additional cohorts ethically collected in Nottingham and Vancouver under their respective institutional approvals. This multi-center design strengthens confidence that the findings are not an artifact of a single population or laboratory protocol.

Perhaps the most clinically tantalizing aspect of the methylation biomarker is its potential compatibility with minimally invasive, blood-based diagnostic assays. Tumor DNA, including methylated fragments, is shed into the bloodstream, and liquid biopsy technologies are rapidly advancing to the point where such fragments can be detected and quantified from a simple blood draw. If KCNK1 methylation can be reliably measured in circulating tumor DNA, it could enable early detection of high-grade serous cancer in asymptomatic women, a goal that has eluded the field despite decades of effort. The authors suggest that the methylation biomarker shows potential for early disease detection and possible utility in blood-based assays, which would represent a paradigm shift from the current reliance on transvaginal ultrasound and CA-125, tools that simply are not sensitive enough to catch the disease when it is most treatable.

Beyond diagnosis, KCNK1 may help solve another vexing clinical problem: identifying patients unlikely to benefit from standard care. High-grade serous cancer is typically treated with cytoreductive surgery followed by platinum-based chemotherapy, yet responses vary enormously, and some patients derive little benefit while enduring significant toxicity. The finding that high KCNK1 immunohistochemical expression independently predicts improved outcome suggests the channel could serve as a stratification tool, flagging patients whose tumors behave more aggressively and who might be candidates for alternative treatment strategies, clinical trials or intensified surveillance. Conversely, the marker could spare patients with favorable biology from unnecessary escalation. Patient stratification of this kind is a cornerstone of precision oncology, and biomarkers that can guide such decisions are desperately needed in gynecological malignancy.

It is worth emphasizing what the study does and does not claim. As a diagnostic marker on its own, KCNK1 mRNA expression, while elevated in cancer, showed low specificity and sensitivity, meaning the transcript alone could not reliably distinguish disease. It is the methylation signature that delivers the near-perfect diagnostic performance. This distinction matters for translational development: the path forward likely involves methylation-based assays rather than simple gene expression tests. The research also remains at the validation stage; prospective clinical studies in large screening populations will be required before KCNK1 methylation could enter routine practice. Nevertheless, the combination of strong diagnostic metrics, independent prognostic value across three cohorts and mechanistic plausibility makes this one of the more promising biomarker stories to emerge in ovarian cancer research in recent years.

The study also carries a poignant human dimension. The authors dedicate the work to the memory of Dr Stephen McQuaid of the Northern Ireland Biobank, a colleague, mentor and friend without whom, they write, the paper and many others would not have been possible. The research was funded by the Belfast Health and Social Care Trust Samaritan Fund, Invest Northern Ireland Proof of Concept Funding, the HSC Research and Development Division of the Public Health Agency in Northern Ireland, and the Cancer Liquid Biopsy Consortium under the North-South Research Program, a collaboration funded through the Government’s Shared Island Fund. That last funding stream is fitting, because the future of this biomarker may well lie in liquid biopsy, the very technology the consortium exists to advance. If subsequent studies confirm the 98 percent sensitivity and specificity figures in blood-based testing, a potassium channel once studied for its electrophysiology could become the early warning system that ovarian cancer patients have been waiting decades for.

Subject of Research: The role of the potassium channel KCNK1 as a diagnostic and prognostic biomarker in high-grade serous ovarian cancer

Article Title: The multifaceted role of the potassium channel KCNK1 in the early detection and prognostication of high-grade serous cancer

Article References: Chatterji, S., Craig, E., Egerton, K., Haddock, P., Beirne, J., Feeney, L., McCluggage, W. G., Leung, S., Gilks, C. B., Storr, S. J., Martin, S. G., McCloskey, K. D., McQuaid, S., Mullan, P., & Buckley, N. E. (2026). The multifaceted role of the potassium channel KCNK1 in the early detection and prognostication of high-grade serous cancer. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02281-w

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02281-w

Keywords: KCNK1, ovarian cancer, high-grade serous cancer, biomarker, DNA methylation, CA-125, early diagnosis, prognosis, potassium channels, liquid biopsy, patient stratification, fallopian tube